MEGAN JOHNSON: Open Payments
NPI 1063864783 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,217 in 63 payments from 18 companies in 2025. Trend: 2023 $872 · 2024 $1,143 · 2025 $1,217
Food & beverage: $1,217
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 17 | $270 |
| Janssen Biotech, Inc. | 11 | $146 |
| Boston Scientific Corporation | 1 | $138 |
| ABBVIE INC. | 4 | $91 |
| Phathom Pharmaceuticals, Inc. | 7 | $69 |
| GENZYME CORPORATION | 2 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Ipsen Biopharmaceuticals, Inc | 2 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $45 |
Products named: REZDIFFRA, AMS 700, TREMFYA, DUPIXENT, RINVOQ, VOQUEZNA, IQIRVO, ENTYVIO.
Industry payments across NE — which companies pay providers there.
